NCT02332980 · OUTCOME

PD-L2 Levels

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · Source last updated 2026-06-24

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 1 year

What was measured

Measured at baseline and during treatment. Summarized descriptively by median, minimum, maximum and interquartile range. Overall response and complete response will be correlated with each measure using Wilcoxon rank sum test. The relationship between each measure and time to event measures will be evaluated using Cox proportional hazard models.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Measured at baseline and during treatment. Summarized descriptively by median, minimum, maximum and interquartile range. Overall response and complete response will be correlated with each measure using Wilcoxon rank sum test. The relationship between each measure and time to event measures will be evaluated using Cox proportional hazard models.
reporting Status: NOT_POSTED
time Frame: Up to 1 year
title: PD-L2 Levels
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice